A61K 2239/25
Suicide switch
A61K2239/25 (Suicide switch) appears on 12 US grants and 54 published applications in this corpus.
Search patents in A61K- Granted patents
- 12
- Published applications
- 54
- Assignees
- 37
- Inventors
- 136
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 2 |
| 2021 | 0 | 4 |
| 2022 | 2 | 3 |
| 2023 | 1 | 8 |
| 2024 | 0 | 12 |
| 2025 | 2 | 10 |
| 2026 | 6 | 12 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer with anti-CD33 immunotherapy25 Aug 2026US 12,714,750 B2Lentigen Technology, Inc.
- Small molecules for dual function positron emission tomography (PET) and cell suicide switches4 Aug 2026US 12,697,403 B2The Trustees of the University of Pennsylvania
- Gene fusions for control of genetically modified cells14 Apr 2026US 12,599,665 B2A2 Biotherapeutics, Inc.
- Methods and compositions for freezing and thawing mammalian cells24 Mar 2026US 12,582,714 B2Takeda Pharmaceutical Company Limited
- Chimeric antigen receptors targeting CD3310 Mar 2026US 12,570,758 B2Fred Hutchinson Cancer Center
- Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof20 Aug 2026US 2026/0240908 A1Fred Hutchinson Cancer Center
- Cell6 Aug 2026US 2026/0224627 A1Autolus Limited
- Molecules that bind to b-cell activating factor receptor polypeptides6 Aug 2026US 2026/0226185 A1Mayo Foundation for Medical Education and Research
- Cd19-specific antibody constructs and compositions thereof30 Jul 2026US 2026/0217822 A1
- Igg derived b7-h3-specific chimeric antigen receptor (b7-h3 car) effector cells for the treatment of cd276+ tumors and autoimmune diseases23 Jul 2026US 2026/0209356 A1
Most cited
By later US patents
- Compositions and methods for treating cancer with anti-CD33 immunotherapy5US 10,426,797 B2Lentigen Technology, Inc. · 2019
- Compositions and methods for treating cancer with anti-CD33 immunotherapy1US 11,464,801 B2Lentigen Technology, Inc. · 2022
- Compositions and methods for adoptive cell therapy for cancer1US 12,241,097 B2Memorial Sloan Kettering Cancer Center · 2025